NCT00779896

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: McGill University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.

Conditions

• Cutaneous T-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Tazarotene	Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-12-01
• Completion: 2012-12-01
• First posted: 2008-10-24
• Last updated: 2008-10-24

Locations

1 site across 1 country: Canada